Pioneering cellular medicines for women’s health

We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer, triple negative breast cancer and endometriosis.

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

Cartherics to Present at Biotech Showcase™ 2023

By Christine Filippis / December 22, 2022
Cartherics to Present at Biotech Showcase™ 2023 Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program...
Read More

Message from the CEO – December 2022

By Christine Filippis / December 14, 2022
This year has been an exciting and productive one for Cartherics. We opened our new and impressive research and development...
Read More

Breaking the Mould: Building a Research-Based Biotech Company in Australia from Scratch

By Christine Filippis / December 7, 2022
Ian Nisbet and Alan Trounson, AO Australia is a very challenging environment for early-stage biotechnology companies. Risk capital is hard...
Read More